Search results
Showing 31 to 45 of 2084 results for technology appraisal
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
Consultation on changes to technology appraisals and highly specialised technologies
What NICE does Our guidance About technology appraisal guidance Our methods and processes (health technology evaluation...
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
This process guide explains how treatment option summaries for multiple guidelines were developed in an open, transparent, and timely way, with appropriate expert input
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
This guideline covers detecting, diagnosing and treating women (aged 18 and over) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer (oesophageal cancer, gastro-oesophageal junction cancer and gastric cancer) in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
In development Reference number: GID-TA10726 Expected publication date: 13 May 2026
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
In development Reference number: GID-MT526 Expected publication date: TBC
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for people by ensuring that they get the most effective tests and treatments, and that they have access to suitable palliative care and follow-up.
Past technology appraisal appeals and decisions
Our methods and processes (health technology evaluation manual)
NICE's technology appraisal and highly specialised technologies guidance manual
We are listening to your views on this Technology appraisal guidance. Comments close 4 June 2026.
Charging procedure for NICE technology appraisal and highly specialised technologies evaluations